GLP-1 for PCOS: How Semaglutide and Tirzepatide May Help Treat It

Matthew Segar

Medically Reviewed

Matthew Segar, MD

Cardiologist, Bioinformatics

Written by Angela Myers

Published: March 24, 2026 15 Min Read
Woman looking at herself in the mirror with hands placed on the sides of her neck, portraying confidence and wellness

Photo Credit: FilippoBacci / iStock

Key Takeaways

  • GLP-1 medications like semaglutide and tirzepatide may help address insulin resistance in PCOS, which plays a central role in hormonal imbalance, weight gain, and metabolic dysfunction.
  • Improvements in weight, blood sugar regulation, and hormone levels may support more regular menstrual cycles and ovulation, though outcomes vary and are not guaranteed.
  • GLP-1s are not fertility treatments, but their metabolic effects may indirectly improve reproductive function in some individuals with PCOS.
  • Clinical benefits often take several months to develop, requiring consistent use and realistic expectations around timing and results.
  • GLP-1 medications should be discontinued at least two months before trying to conceive due to safety considerations during pregnancy.

Some medical conditions make it harder to lose weight. One of those conditions is polycystic ovarian syndrome (PCOS), a common hormonal health disorder that impacts about 10-13% of people who menstruate. PCOS is also associated with insulin resistance and a higher risk for diabetes. GLP-1 medications may help with weight loss and blood sugar regulation, which is why GLP-1s for PCOS is such a hot topic.

Continue reading to learn what weight loss medications can realistically do for people with PCOS and how GLP-1s might impact other symptoms and overall hormonal health.

Why PCOS Impacts Metabolism

PCOS is a hormonal health condition, meaning it creates an imbalance in hormones, the body’s chemical messengers. When hormones are disrupted, it can have a ripple effect on many areas of health, including metabolism or how fast your body turns food into energy.

PCOS affects many hormones that play a role in metabolic health. These include:

  • Cortisol: People with PCOS typically have higher levels of cortisol. Although it’s nicknamed the stress hormone, higher cortisol levels can lead to greater fat storage, particularly around the belly.
  • Leptin: People with PCOS have higher levels of leptin, an appetite regulating hormone, which can make them leptin resistant. Leptin resistance means the hormone is no longer as effective at regulating appetite.
  • Androgens: Androgens are known as “male sex hormones,” but everyone has some level of androgens regardless of gender. People with PCOS have higher levels than necessary, which can disrupt glucose metabolism, or how the body breaks down food into glucose that can be used for energy. When this process is disrupted, the body stores more fat.
  • Insulin: Last but not least is insulin, a hormone involved in fat storage and regulating blood sugar levels. Somewhere between 35-80% of people with PCOS are insulin resistant, meaning this hormone doesn’t work as intended. In turn, this impacts overall metabolic health and may contribute to weight gain.

Imbalances in the above hormones may also lead to other symptoms that aren’t directly related to weight, such as hair loss on the scalp, hormonal acne, hair growth on the body, fatigue, an irregular period, and fertility problems.

The Role of Insulin Resistance in Hormonal Imbalance

Out of all the hormones above, insulin is particularly important for weight management. When we consume food, our body breaks it down into glucose which then enters the bloodstream. The pancreas (an internal organ in the abdomen) then creates insulin to help get the glucose into cells that use it as energy. Any glucose that doesn’t enter those cells remains in the bloodstream, which is measured as someone’s blood sugar level.

When blood sugar levels are too high for months or years, the body creates more insulin. Over time, the cells stop responding to insulin’s effects, a condition known as insulin resistance.

The body has to store the excess glucose somewhere since it can’t stay in the bloodstream. It is temporarily stored in muscles and the liver, though when those are at capacity, the body stores it as fat, which leads to weight gain. Alongside weight gain, insulin resistance can increase the risk of type 2 diabetes.

Researchers are still exploring if there’s a correlation or causation between PCOS and insulin resistance. We do, however, know that people with PCOS are more likely to develop it, and over half of people with PCOS develop type 2 diabetes before they turn 40.

PCOS weight gain has a root cause. GLP-1s may address it.

PCOS weight gain has a root cause. GLP-1s may address it.

GLP-1 medications may help improve insulin resistance, support meaningful weight loss, and positively impact hormonal balance. Take SkinnyRx's quick assessment to see if a prescription may be right for you, reviewed by a licensed provider.

How GLP-1s May Help With PCOS

GLP-1s are a medication class that mimic a naturally occurring hormone by the same name. This hormone is involved in appetite regulation and blood sugar regulation. Its effects are well-known for weight loss and insulin resistance, two common struggles for people with PCOS, though it may help with other symptoms too.

A 2025 meta-analysis analyzed various clinical trials and studies on GLP-1 medications’ effects on PCOS. It found that these medications may facilitate weight loss, help regulate blood sugar levels, and may even offer hormonal health benefits, such as improved menstrual cycle regularity.

Insulin Resistance

GLP-1s are a class of medications that mimic a naturally occurring hormone by the same name. Both the naturally occurring hormone and these medications help the body produce appropriate insulin levels.

Admittedly, researchers are still investigating the exact ways that GLP-1 impacts insulin, but a leading theory is that GLP-1s regulate beta cell activity, leading to insulin regulation.

Weight Management

The weight loss benefits of GLP-1s are well-documented in clinical trials. However, those trials don’t often focus specifically on people with PCOS. There are some exceptions, and trials in populations with PCOS suggest GLP-1s are an effective weight management tool for people with this condition.

GLP-1 medications, such Wegovy and Zepbound, impact weight in a few key ways:

  • Reduce fat storage in the belly: PCOS increases fat storage, particularly around the belly. Fat in this location is called visceral fat, and it’s more likely to negatively affect metabolism and heart health than other types. In clinical trials, GLP-1s led to significant reductions in visceral fat, though these studies took place in populations with obesity. PCOS-specific data is still evolving.
  • Balance hunger hormones: While PCOS increases ghrelin levels and lowers leptin levels, GLP-1s do the opposite. They increase leptin levels, leading to improved appetite control, and decrease ghrelin levels, which may decrease food noise.
  • Improve insulin sensitivity: Last but not least, insulin sensitivity also plays a role in weight management. When insulin is properly regulated, less blood sugar gets stored as fat in the body.

GLP-1 for PCOS infographic showing insulin resistance, hormonal imbalance, blood sugar regulation, ovulation, and pregnancy considerations with semaglutide and tirzepatide

An End to the "Sugar Crash" Cycle

Another common PCOS symptom is fatigue, which is in part related to poor blood sugar regulation. When someone has insulin resistance, they may experience a more intense blood sugar spike after eating, followed by a crash that can lead to fatigue and hunger.

Since GLP-1s slow digestion, someone with PCOS may avoid this spike and feel full for longer.

Possible Effect on Androgen Hormones

GLP-1s’ role in managing appetite, weight, and blood sugar levels has led doctors to prescribe these medications to people with PCOS. Interestingly, these medications not only impact metabolic health but may also have an impact on androgen hormones.

As a hormonal health condition, PCOS often leads to hyperandrogenism, which is when someone who menstruates produces more androgen hormones than necessary. In some studies, GLP-1s play a modest regulatory role for these hormones, meaning weight loss medications may help people with PCOS experience more balanced androgen levels.

However, results are varied, with some studies suggesting the type of GLP-1 may matter. For example, semaglutide may have a more significant impact on androgen hormones than liraglutide.

Hormonal Acne and Reducing Hirsutism

Two PCOS symptoms related to hyperandrogenism are hormonal acne and hirsutism, which is when someone has excess hair growth on their body and hair loss on their scalp. In theory, GLP-1s might help with these symptoms, though there is a lack of clinical evidence to support this benefit.

Potential to Help With Reproductive Function

PCOS may disrupt menstrual cycle regularity, which is of particular concern to people trying to get pregnant. Limited evidence suggests GLP-1s improve menstrual cycle regularity for people with PCOS. That means if someone with PCOS who has inconsistent periods takes a GLP-1, they may find their period becomes more predictable.

A 2026 meta-review takes this finding a step further, suggesting GLP-1s may positively impact ovarian functioning, possibly increasing fertility. Again, the research is limited, and much of the clinical trials we do have on this topic were animal studies, so the results might not translate to people with PCOS.

GLP-1s may be a real option for PCOS

GLP-1s may be a real option for PCOS

Stubborn weight gain is one of PCOS's hardest symptoms to treat. Find out if a GLP-1 prescription may be an option for you.

The "Ozempic Baby" Phenomenon: Fertility and Safety

People on social media are reporting “Ozempic babies,” which has led some women to believe GLP-1s may increase fertility. This probably isn’t true for most women, though a 2025 study found it might increase the chance of conception for some people with PCOS.

This is due to how GLP-1s could restore menstrual regularity for some people with PCOS. While we often think of menstruation as monthly periods, that’s just one part of this cycle. Another is ovulation, when the ovary releases an egg and fertility is at its highest.

When someone’s cycle becomes more regular and consistent, they experience ovulation on a more predictable timeline, which may lead to a higher chance of conceiving.

Another reason why GLP-1s may increase fertility is that some GLP-1 medications may impact oral contraceptives, aka birth control pills.

Mounjaro and Zepbound have the strongest labeled interaction with contraceptives. These often require a non-oral backup, such as condoms, for four weeks after initiation and any time the dosage increases.

Other medications with GLP-1s have limited to no evidence of affecting oral contraceptives, but discuss any potential interactions with a healthcare provider beforehand.

The "Washout Period": Why You Must Stop Before Conceiving

While GLP-1s may increase fertility, drug manufacturers do not recommend taking most GLP-1s when trying to get pregnant. In fact, Wegovy, Ozempic, and Rybelsus all have a two-month “washout period,” meaning someone should stop taking these medications at least two months before trying to conceive.

This is because we unfortunately don’t have a lot of clinical data around GLP-1s and pregnancy, and more research is required to determine if these medications are safe for the parent and baby.

Comparing the Options: Semaglutide vs. Tirzepatide for PCOS

Semaglutide and tirzepatide are two types of weight loss medications. Both have demonstrated meaningful weight loss, insulin sensitivity improvements, and possible hormonal health benefits for people with PCOS. However, if someone’s goal is weight management, tirzepatide might be the better option.

Is the GIP Component in Zepbound a Game Changer?

In a 2025 clinical trial, people who took tirzepatide experienced an average weight loss of -20.2%, while those who took semaglutide lost -13.7% on average. The reason why tirzepatide may be more effective is that it mimics two hormones involved in weight management: GLP-1 and GIP.

Managing PCOS Symptoms Beyond Weight

GLP-1 medications may help people with PCOS improve insulin sensitivity and meet weight loss goals. There’s also limited evidence that these medications might improve menstrual regularity, reduce androgen hormones, and help with other PCOS symptoms, though more research is needed to confirm these effects. If curious about whether a GLP-1 medication may help manage PCOS, talk to a trusted healthcare provider about this treatment option.

For those actively exploring their options, SkinnyRx offers a quick assessment reviewed by licensed clinicians to help determine whether a GLP-1 prescription may be appropriate for your health history and goals. It takes just a few minutes and carries no obligation to proceed.

Frequently Asked Questions

GLP-1s may be considered for some people with PCOS, though Metformin is still the standard treatment. Both help with insulin resistance, but only medications in the GLP-1 medication class are FDA-approved for weight management, making it a more attractive option for people with PCOS who are looking to lose weight.


GLP-1s can help restore menstrual cycle regularity for people with PCOS. Some people experience a regular period return within six months of taking a GLP-1, though there isn’t a guaranteed timeline, and this effect may not happen for everyone.


Semaglutide might help with PCOS-related hair loss. For people with PCOS, hair loss stems from hormonal imbalances, such as insulin resistance and higher testosterone levels. GLP-1s may help with insulin resistance and affect testosterone levels, which could indirectly help with PCOS-related hair loss.


Usually, it is not considered safe to take GLP-1 medications, like Wegovy and Ozempic, when trying to conceive. Novo Nordisk, the drug manufacturer, recommends a two-month wash-out period, meaning someone should stop taking these medications two months before trying to get pregnant.


  1. Teede HJ, Tay CT, Laven JJE, Dokras A, Moran LJ, Piltonen TT, Costello MF, Boivin J, Redman LM, Boyle JA, Norman RJ, Mousa A, Joham AE. Recommendations From the 2023 International Evidence-based Guideline for the Assessment and Management of Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2023 Sep 18;108(10):2447-2469. doi: 10.1210/clinem/dgad463. PMID: 37580314; PMCID: PMC10505534: https://academic.oup.com/jcem/article/108/10/2447/7242360
  2. MedlinePlus. Hormones [Internet]. Bethesda (MD): U.S. National Library of Medicine; [updated 2025 Nov 18; cited 2026 Mar 23]. Available from: https://medlineplus.gov/hormones.html
  3. Heydari T, Ramdass PVAK. Circadian rhythm disruption and polycystic ovary syndrome: a systematic review and meta-analysis. AJOG Glob Rep. 2025 Mar 20;5(2):100479. doi: 10.1016/j.xagr.2025.100479. PMID: 40292350; PMCID: PMC12032313: https://pmc.ncbi.nlm.nih.gov/articles/PMC12032313/
  4. Kumar R, Rizvi MR, Saraswat S. Obesity and Stress: A Contingent Paralysis. Int J Prev Med. 2022 Jun 24;13:95. doi: 10.4103/ijpvm.IJPVM_427_20. PMID: 35958362; PMCID: PMC9362746: https://pmc.ncbi.nlm.nih.gov/articles/PMC9362746/
  5. Reesor M, Goudiaby Y, Grossett N, Zand N, Chichester R, Echevarria-Javier L, Vysochyn M, Alam A. Effect of Hyperinsulinemia on Leptin and Ghrelin Levels in Polycystic Ovarian Syndrome: A Meta-Analysis. Cureus. 2024 Sep 9;16(9):e69023. doi: 10.7759/cureus.69023. PMID: 39385878; PMCID: PMC11464008: https://pmc.ncbi.nlm.nih.gov/articles/PMC11464008/
  6. Skoracka K, Hryhorowicz S, Schulz P, Zawada A, Ratajczak-Pawłowska AE, Rychter AM, et al. The role of leptin and ghrelin in the regulation of appetite in obesity. Peptides. 2025 Apr;186:171367. doi: 10.1016/j.peptides.2025.171367. Epub 2025 Feb 19. PMID: 39983918: https://www.sciencedirect.com/science/article/pii/S0196978125000282
  7. Alemany M. The Roles of Androgens in Humans: Biology, Metabolic Regulation and Health. Int J Mol Sci. 2022 Oct 8;23(19):11952. doi: 10.3390/ijms231911952. PMID: 36233256; PMCID: PMC9569951: https://pmc.ncbi.nlm.nih.gov/articles/PMC9569951/
  8. Wang K, Li Y, Chen Y. Androgen excess: a hallmark of polycystic ovary syndrome. Front Endocrinol (Lausanne). 2023 Dec 13;14:1273542. doi: 10.3389/fendo.2023.1273542. PMID: 38152131; PMCID: PMC10751361: https://pmc.ncbi.nlm.nih.gov/articles/PMC10751361/
  9. Raeisi-Dehkordi H, Thorand B, Beigrezaei S, Peters A, Rathmann W, Adamski J, et al. The mediatory role of androgens on sex differences in glucose homeostasis and incidence of type 2 diabetes: the KORA study. Cardiovasc Diabetol. 2024 Nov 15;23(1):411. doi: 10.1186/s12933-024-02494-7. PMID: 39548547; PMCID: PMC11568628: https://pmc.ncbi.nlm.nih.gov/articles/PMC11568628/
  10. National Institute of Diabetes and Digestive and Kidney Diseases. Insulin resistance & prediabetes [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; [reviewed 2025 Mar; cited 2026 Mar 23]. Available from: https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/prediabetes-insulin-resistance
  11. Amisi CA. Markers of insulin resistance in Polycystic ovary syndrome women: An update. World J Diabetes. 2022 Mar 15;13(3):129-149. doi: 10.4239/wjd.v13.i3.129. PMID: 35432749; PMCID: PMC8984569: https://pmc.ncbi.nlm.nih.gov/articles/PMC8984569/
  12. Centers for Disease Control and Prevention. About insulin resistance and type 2 diabetes [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; [updated 2024 May 15; cited 2026 Mar 23]. Available from: https://www.cdc.gov/diabetes/about/insulin-resistance-type-2-diabetes.html
  13. Centers for Disease Control and Prevention. Diabetes and polycystic ovary syndrome (PCOS) [Internet]. Atlanta (GA): Centers for Disease Control and Prevention; [updated 2024 May 15; cited 2026 Mar 23]. Available from: https://www.cdc.gov/diabetes/risk-factors/pcos-polycystic-ovary-syndrome.html
  14. Kommu S, Whitfield P. Semaglutide [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–. [updated 2024 Feb 11; cited 2026 Mar 23]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK603723/
  15. Diakosavvas M, Oyebode O, Bhide P. Weight Management Strategies to Reduce Metabolic Morbidity in Women With Polycystic Ovary Syndrome. Curr Obes Rep. 2025 Mar 6;14(1):22. doi: 10.1007/s13679-025-00614-2. PMID: 40045077; PMCID: PMC11882674: https://link.springer.com/article/10.1007/s13679-025-00614-2#Sec6
  16. Zheng Z, Zong Y, Ma Y, Tian Y, Pang Y, Zhang C, Gao J. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024 Sep 18;9(1):234. doi: 10.1038/s41392-024-01931-z. PMID: 39289339; PMCID: PMC11408715: https://www.nature.com/articles/s41392-024-01931-z
  17. Luo Y, Li JE, Zeng H, Zhang Y, Yang S, Liu J. Semaglutide alleviates the pancreatic β cell function via the METTL14 signaling and modulating gut microbiota in type 2 diabetes mellitus mice. Life Sci. 2025 Jan 15;361:123328. doi: 10.1016/j.lfs.2024.123328. Epub 2024 Dec 22. PMID: 39719165: https://www.sciencedirect.com/science/article/abs/pii/S0024320524009184
  18. Hoteit BH, Kotaich J, Ftouni H, Hazime F, Safawi A, Masri R, Marwani M. The dual impact of GLP-1 receptor agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials. Ther Adv Endocrinol Metab. 2025 Oct 7;16:20420188251383064. doi: 10.1177/20420188251383064. PMID: 41069706; PMCID: PMC12504844: https://pmc.ncbi.nlm.nih.gov/articles/PMC12504844/
  19. Saad RK, Ghezzawi M, Horanieh R, Khamis AM, Saunders KH, Batsis JA, Chakhtoura M. Abdominal Visceral Adipose Tissue and All-Cause Mortality: A Systematic Review. Front Endocrinol (Lausanne). 2022 Aug 22;13:922931. doi: 10.3389/fendo.2022.922931. PMID: 36082075; PMCID: PMC9446237: https://pmc.ncbi.nlm.nih.gov/articles/PMC9446237/
  20. Liao C, Liang X, Zhang X, Li Y. The effects of GLP-1 receptor agonists on visceral fat and liver ectopic fat in an adult population with or without diabetes and nonalcoholic fatty liver disease: A systematic review and meta-analysis. PLoS One. 2023 Aug 24;18(8):e0289616. doi: 10.1371/journal.pone.0289616. PMID: 37616255; PMCID: PMC10449217: https://pmc.ncbi.nlm.nih.gov/articles/PMC10449217/
  21. Aldawsari M, Almadani FA, Almuhammadi N, Algabsani S, Alamro Y, Aldhwayan M. The Efficacy of GLP-1 Analogues on Appetite Parameters, Gastric Emptying, Food Preference and Taste Among Adults with Obesity: Systematic Review of Randomized Controlled Trials. Diabetes Metab Syndr Obes. 2023 Mar 2;16:575-595. doi: 10.2147/DMSO.S387116. PMID: 36890965; PMCID: PMC9987242: https://pmc.ncbi.nlm.nih.gov/articles/PMC9987242/
  22. Ee C, Pirotta S, Mousa A, Moran L, Lim S. Providing lifestyle advice to women with PCOS: an overview of practical issues affecting success. BMC Endocr Disord. 2021 Nov 23;21(1):234. doi: 10.1186/s12902-021-00890-8. PMID: 34814919; PMCID: PMC8609880: https://pmc.ncbi.nlm.nih.gov/articles/PMC8609880/
  23. Hall H, Perelman D, Breschi A, Limcaoco P, Kellogg R, McLaughlin T, Snyder M. Glucotypes reveal new patterns of glucose dysregulation. PLoS Biol. 2018 Jul 24;16(7):e2005143. doi: 10.1371/journal.pbio.2005143. PMID: 30040822; PMCID: PMC6057684: https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.2005143
  24. Austregésilo de Athayde De Hollanda Morais B, Martins Prizão V, de Moura de Souza M, Ximenes Mendes B, Rodrigues Defante ML, Cosendey Martins O, et al. The efficacy and safety of GLP-1 agonists in PCOS women living with obesity in promoting weight loss and hormonal regulation: A meta-analysis of randomized controlled trials. J Diabetes Complications. 2024 Oct;38(10):108834. doi: 10.1016/j.jdiacomp.2024.108834. Epub 2024 Aug 20. PMID: 39178623: https://pubmed.ncbi.nlm.nih.gov/39178623/
  25. Akel M, Ziq A, Kaldas P, Hamden J, Omari AR, Silanee A. Exploring the Therapeutic Potential of Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists in Polycystic Ovary Syndrome. Cureus. 2024 Nov 14;16(11):e73687. doi: 10.7759/cureus.73687. PMID: 39677183; PMCID: PMC11646169: https://pmc.ncbi.nlm.nih.gov/articles/PMC11646169/
  26. Szczesnowicz A, Szeliga A, Niwczyk O, Bala G, Meczekalski B. Do GLP-1 Analogs Have a Place in the Treatment of PCOS? New Insights and Promising Therapies. J Clin Med. 2023 Sep 12;12(18):5915. doi: 10.3390/jcm12185915. PMID: 37762856; PMCID: PMC10532286: https://pmc.ncbi.nlm.nih.gov/articles/PMC10532286/
  27. Voros C, Chatzinikolaou F, Papapanagiotou I, Polykalas S, Mavrogianni D, Koulakmanidis AM, et al. A Systematic Review on GLP-1 Receptor Agonists in Reproductive Health: Integrating IVF Data, Ovarian Physiology and Molecular Mechanisms. Int J Mol Sci. 2026 Jan 12;27(2):759. doi: 10.3390/ijms27020759. PMID: 41596408; PMCID: PMC12841515: https://pmc.ncbi.nlm.nih.gov/articles/PMC12841515/
  28. Merhi Z, Karekar M, Mouanness M. GLP-1 receptor agonist for weight loss and fertility: Social media and online perception versus evidence-based medicine. PLoS One. 2025 Jul 2;20(7):e0326210. doi: 10.1371/journal.pone.0326210. PMID: 40601607; PMCID: PMC12221084: https://pmc.ncbi.nlm.nih.gov/articles/PMC12221084/#sec024
  29. Pavli P, Triantafyllidou O, Kapantais E, Vlahos NF, Valsamakis G. Infertility Improvement after Medical Weight Loss in Women and Men: A Review of the Literature. Int J Mol Sci. 2024 Feb 5;25(3):1909. doi: 10.3390/ijms25031909. PMID: 38339186; PMCID: PMC10856238: https://pubmed.ncbi.nlm.nih.gov/38339186/
  30. National Health Service. Periods and fertility in the menstrual cycle [Internet]. London: National Health Service; [reviewed 2023 Jan 05; cited 2026 Mar 23]. Available from: https://www.nhs.uk/conditions/periods/fertility-in-the-menstrual-cycle/
  31. U.S. Food and Drug Administration. Mounjaro (tirzepatide) injection, for subcutaneous use [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2022 [cited 2026 Mar 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215866s000lbl.pdf
  32. U.S. Food and Drug Administration. Zepbound (tirzepatide) injection, for subcutaneous use [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2025 [cited 2026 Mar 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/217806Orig1s020lbl.pdf
  33. U.S. Food and Drug Administration. Ozempic (semaglutide) injection, for subcutaneous use [Internet]. Silver Spring (MD): U.S. Food and Drug Administration; 2017 [cited 2026 Mar 23]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209637lbl.pdf
  34. Aronne LJ, Horn DB, le Roux CW, Ho W, Falcon BL, Gomez Valderas E, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025 Jul 3;393(1):26-36. doi: 10.1056/NEJMoa2416394. Epub 2025 May 11. PMID: 40353578: https://www.nejm.org/doi/full/10.1056/NEJMoa2416394
  35. Seino Y, Fukushima M, Yabe D. GIP and GLP-1, the two incretin hormones: Similarities and differences. J Diabetes Investig. 2010 Apr 22;1(1-2):8-23. doi: 10.1111/j.2040-1124.2010.00022.x. PMID: 24843404; PMCID: PMC4020673: https://pmc.ncbi.nlm.nih.gov/articles/PMC4020673/
Angela Myers

By Angela Myers

Contributing Author

Angela Myers is a freelance health writer covering weight management, healthy aging, and nutrition. Her work has appeared in AARP, Well+Good, and Forbes, among others. Before starting her writing career, she conducted award-winning research on how to improve sexual violence prevention courses on college campuses. That research sparked a passion for health communication, and she's been writing about making healthcare accessible and inclusive ever since.